Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 32
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

CXCR4+-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis

  • Cano-Garrido, Olivia
  • Céspedes, María Virtudes
  • Unzueta, Ugutz
  • Saccardo, Paolo
  • Roldán, Mònica
  • Sánchez-Chardi, Alejandro
  • Cubarsi, Rafael
  • Vázquez, Esther
  • Mangues, Ramon
  • García-Fruitós, Elena
  • Villaverde, Antonio
Aim: Lactococcus lactis is a Gram-positive (endotoxin-free) food-grade bacteria exploited as alternative to Escherichia coli for recombinant protein production. We have explored here for the first time the ability of this platform as producer of complex, self-assembling protein materials. Materials & methods: Biophysical properties, cell penetrability and in vivo biodistribution upon systemic administration of tumor-targeted protein nanoparticles produced in L. lactis have been compared with the equivalent material produced in E. coli. Results: Protein nanoparticles have been efficiently produced in L. lactis, showing the desired size, internalization properties and biodistribution. Conclusion: In vitro and in vivo data confirm the potential and robustness of the production platform, pointing out L. lactis as a fascinating cell factory for the biofabrication of protein materials intended for therapeutic applications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CXCR4+-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis

  • Cano-Garrido, Olivia
  • Céspedes, María Virtudes
  • Unzueta, Ugutz
  • Saccardo, Paolo
  • Roldán, Mònica
  • Sánchez-Chardi, Alejandro
  • Cubarsi, Rafael
  • Vázquez, Esther
  • Mangues, Ramon
  • García-Fruitós, Elena
  • Villaverde, Antonio
Aim: Lactococcus lactis is a Gram-positive (endotoxin-free) food-grade bacteria exploited as alternative to Escherichia coli for recombinant protein production. We have explored here for the first time the ability of this platform as producer of complex, self-assembling protein materials. Materials & methods: Biophysical properties, cell penetrability and in vivo biodistribution upon systemic administration of tumor-targeted protein nanoparticles produced in L. lactis have been compared with the equivalent material produced in E. coli. Results: Protein nanoparticles have been efficiently produced in L. lactis, showing the desired size, internalization properties and biodistribution. Conclusion: In vitro and in vivo data confirm the potential and robustness of the production platform, pointing out L. lactis as a fascinating cell factory for the biofabrication of protein materials intended for therapeutic applications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

  • Pesarrodona, Mireia
  • Jauset González, Antoni
  • Sánchez-Chardi, Alejandro
  • Seras Franzoso, Joaquin
  • Baltà Foix, Ricardo
  • Mancilla Zamora, Sandra
  • Fernández Amurgo, Yolanda
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Biofabrication; Cancer therapy; Functional amyloids, Biofabricación; Terapia contra el cáncer; Amiloides funcionales, Biofabricació; Teràpia contra el càncer; Amiloides funcionals, Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins., This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4⁺ colorectal cancer models

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sala Faig, Rita
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Pavón Ribas, Miguel Ángel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Trias Folch, Manuel
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Unliganded drug-nanoconjugates accumulate passively in the tumor whereas liganded nanoconjugates promote drug internalization in tumor cells via endocytosis and increase antitumor efficacy. Whether or not tumor cell internalization associates with enhanced tumor uptake is still under debate. We here compared tumor uptake of T22-GFP-H6, a liganded protein carrier targeting the CXCR4 receptor, and the unliganded GFP-H6 carrier in subcutaneous and metastatic colorectal cancer models. T22-GFP-H6 had a higher tumor uptake in primary tumor and metastatic foci than GFP-H6, with no biodistribution or toxicity on normal tissues. T22-GFP-H6 was detected in target CXCR4+ tumor cell cytosol whereas GFP-H6 was detected in tumor stroma. SDF1-α co-administration switched T22-GFP-H6 internalization from CXCR4+ tumor epithelial cells to the stroma. Therefore, the incorporation of a targeting ligand promotes selective accumulation of the nanocarrier inside target tumor cells while increasing whole tumor uptake in a CXCR4-dependent manner, validating T22-GFP-H6 as a CXCR4-targeted drug carrier.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant pharmaceuticals from microbial cells, a 2015 update

  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Martín, Lucas
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Poly-histidine peptides such as H6 (HHHHHH) are used in protein biotechnologies as purification tags, protein-assembling agents and endosomal-escape entities. The pleiotropic properties of such peptides make them appealing to design protein-based smart materials or nanoparticles for imaging or drug delivery to be produced in form of recombinant proteins. However, the clinical applicability of H6-tagged proteins is restricted by the potential immunogenicity of these segments. In this study, we have explored several humanized histidine-rich peptides in tumor-targeted modular proteins, which can specifically bind and be internalized by the target cells through the tumoral marker CXCR4. We were particularly interested in exploring how protein purification, self-assembling and endosomal escape perform in proteins containing the variant histidine-rich tags. Among the tested candidates, the peptide H5E (HEHEHEHEH) is promising as a good promoter of endosomal escape of the associated full-length protein upon endosomal internalization. The numerical modelling of cell penetration and endosomal escape of the tested proteins has revealed a negative relationship between the amount of protein internalized into target cells and the efficiency of cytoplasmic release. This fact demonstrates that the His-mediated, proton sponge-based endosomal escape saturates at moderate amounts of internalized protein, a fact that might be critical for the design of protein materials for cytosolic molecular delivery.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Artificial inclusion bodies for clinical development

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Álamo, Patricia|||0000-0003-0510-5701
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Nolan, Verónica
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Bacterial inclusion bodies (IBs) are mechanically stable protein particles in the microscale, which behave as robust, slow-protein-releasing amyloids. Upon exposure to cultured cells or upon subcutaneous or intratumor injection, these protein materials secrete functional IB polypeptides, functionally mimicking the endocrine release of peptide hormones from secretory amyloid granules. Being appealing as delivery systems for prolonged protein drug release, the development of IBs toward clinical applications is, however, severely constrained by their bacterial origin and by the undefined and protein-to-protein, batch-to-batch variable composition. In this context, the de novo fabrication of artificial IBs (ArtIBs) by simple, cell-free physicochemical methods, using pure components at defined amounts is proposed here. By this, the resulting functional protein microparticles are intriguing, chemically defined biomimetic materials that replicate relevant functionalities of natural IBs, including mammalian cell penetration and local or remote release of functional ArtIB-forming protein. In default of severe regulatory issues, the concept of ArtIBs is proposed as a novel exploitable category of biomaterials for biotechnological and biomedical applications, resulting from simple fabrication and envisaging soft developmental routes to clinics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Selective depletion of metastatic stem cells as therapy for human colorectal cancer

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Aviñó, Ana|||0000-0003-3047-738X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sala, Rita
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Eritja, Ramon|||0000-0001-5383-9334
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Selective elimination of metastatic stem cells (MetSCs) promises to block metastatic dissemination. Colorectal cancer (CRC) cells overexpressing CXCR4 display trafficking functions and metastasis-initiating capacity. We assessed the antimetastatic activity of a nanoconjugate (T22-GFP-H6-FdU) that selectively delivers Floxuridine to CXCR4 cells. In contrast to free oligo-FdU, intravenous T22-GFP-H6-FdU selectively accumulates and internalizes in CXCR4 cancer cells, triggering DNA damage and apoptosis, which leads to their selective elimination and to reduced tumor re-initiation capacity. Repeated T22-GFP-H6-FdU administration in cell line and patient-derived CRC models blocks intravasation and completely prevents metastases development in 38-83% of mice, while showing CXCR4 expression-dependent and site-dependent reduction in foci number and size in liver, peritoneal, or lung metastases in the rest of mice, compared to free oligo-FdU. T22-GFP-H6-FdU induces also higher regression of established metastases than free oligo-FdU, with negligible distribution or toxicity in normal tissues. This targeted drug delivery approach yields potent antimetastatic effect, through selective depletion of metastatic CXCR4 cancer cells, and validates metastatic stem cells (MetSCs) as targets for clinical therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CXCR4+-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Saccardo, Paolo|||0000-0002-3092-1404
  • Roldán, M.
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Cubarsi, Rafael
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Villaverde, Antonio|||0000-0002-2615-4521
Aim: Lactococcus lactis is a Gram-positive (endotoxin-free) food-grade bacteria exploited as alternative to Escherichia coli for recombinant protein production. We have explored here for the first time the ability of this platform as producer of complex, self-assembling protein materials. Materials & methods: Biophysical properties, cell penetrability and in vivo biodistribution upon systemic administration of tumor-targeted protein nanoparticles produced in L. lactis have been compared with the equivalent material produced in E. coli. Results: Protein nanoparticles have been efficiently produced in L. lactis, showing the desired size, internalization properties and biodistribution. Conclusion: In vitro and in vivo data confirm the potential and robustness of the production platform, pointing out L. lactis as a fascinating cell factory for the biofabrication of protein materials intended for therapeutic applications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles

  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Crosas, Eva|||0000-0002-2408-0071
  • Cubarsi, Rafael
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Saccardo, Paolo|||0000-0002-3092-1404
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Rueda, Fabian
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Self-assembling proteins are gaining attention as building blocks for application-tailored nanoscale materials. This is mostly due to the biocompatibility, biodegradability, and functional versatility of peptide chains. Such a potential for adaptability is particularly high in the case of recombinant proteins, which are produced in living cells and are suitable for genetic engineering. However, how the cell factory itself and the particular protein folding machinery influence the architecture and function of the final material is still poorly explored. In this study we have used diverse analytical approaches, including small-angle X-ray scattering (SAXS) and field emission scanning electron microscopy (FESEM) to determine the fine architecture and geometry of recombinant, tumor-targeted protein nanoparticles of interest as drug carriers, constructed on a GFP-based modular scheme. A set of related oligomers were produced in alternative Escherichia coli strains with variant protein folding networks. This resulted in highly regular populations of morphometric types, ranging from 2.4 to 28 nm and from spherical- to rod-shaped materials. These differential geometric species, whose relative proportions were determined by the features of the producing strain, were found associated with particular fluorescence emission, cell penetrability and receptor specificity profiles. Then, nanoparticles with optimal properties could be analytically identified and further isolated from producing cells for use. The cell's protein folding machinery greatly modulates the final geometry reached by the constructs, which in turn defines the key parameters and biological performance of the material.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanostructure empowers active tumor targeting in ligand-based molecular delivery

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Sala, Rita
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Álamo, Patricia|||0000-0003-0510-5701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Cell-selective targeting is expected to enhance effectiveness and minimize side effects of cytotoxic agents. Functionalization of drugs or drug nanoconjugates with specific cell ligands allows receptor-mediated selective cell delivery. However, it is unclear whether the incorporation of an efficient ligand into a drug vehicle is sufficient to ensure proper biodistribution upon systemic administration, and also at which extent biophysical properties of the vehicle may contribute to the accumulation in target tissues during active targeting. To approach this issue, structural robustness of self-assembling, protein-only nanoparticles targeted to the tumoral marker CXCR4 is compromised by reducing the number of histidine residues (from six to five) in a histidine-based architectonic tag. Thus, the structure of the resulting nanoparticles, but not of building blocks, is weakened. Upon intravenous injection in animal models of human CXCR4 colorectal cancer, the administered material loses the ability to accumulate in tumor tissue, where it is only transiently found. It instead deposits in kidney and liver. Therefore, precise cell-targeted delivery requires not only the incorporation of a proper ligand that promotes receptor-mediated internalization, but also, unexpectedly, its maintenance of a stable multimeric nanostructure that ensures high ligand exposure and long residence time in tumor tissue.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein-driven nanomedicines in oncotherapy

  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
Proteins are organic macromolecules essential in life but exploited, mainly in recombinant versions, as drugs or vaccine components, among other uses in industry or biomedicine. In oncology, individual proteins or supramolecular complexes have been tailored as small molecular weight drug carriers for passive or active tumor cell-targeted delivery, through the de novo design of appropriate drug stabilizing vehicles, or by generating constructs with different extents of mimesis of natural cell-targeted entities, such as viruses. In most of these approaches, a convenient nanoscale size is achieved through the oligomeric organization of the protein component in the drug conjugate. Among the different taken strategies, highly cytotoxic proteins such as microbial or plant toxins have been conveniently engineered to self-assemble as self-delivered virus-like, nanometric structures, chemically homogeneous that target metastatic cancer stem cells for the destruction of metastasis in absence of any partner vehicle.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bacterial inclusion bodies are industrially exploitable amyloids

  • de Marco, Ario|||0000-0001-7729-819X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Mitraki, Anna
  • Peternel, Spela
  • Rinas, Ursula
  • Trujillo-Roldán, Mauricio A.
  • Valdez-Cruz, Norma A.
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Understanding the structure, functionalities and biology of functional amyloids is an issue of emerging interest. Inclusion bodies, namely protein clusters formed in recombinant bacteria during protein production processes, have emerged as unanticipated, highly tunable models for the scrutiny of the physiology and architecture of functional amyloids. Based on an amyloidal skeleton combined with varying amounts of native or native-like protein forms, bacterial inclusion bodies exhibit an unusual arrangement that confers mechanical stability, biological activity and conditional protein release, being thus exploitable as versatile biomaterials. The applicability of inclusion bodies in biotechnology as enriched sources of protein and reusable catalysts, and in biomedicine as biocompatible topographies, nanopills or mimetics of endocrine secretory granules has been largely validated. Beyond these uses, the dissection of how recombinant bacteria manage the aggregation of functional protein species into structures of highly variable complexity offers insights about unsuspected connections between protein quality (conformational status compatible with functionality) and cell physiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer

  • Sala, Rita
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Roldán, Mònica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
By the appropriate selection of functional peptides and proper accommodation sites, we have generated a set of multifunctional proteins that combine selectivity for CXCR4 cell binding and relevant endosomal escape capabilities linked to the viral peptide HA2. In particular, the construct T22-GFP-HA2-H6 forms nanoparticles that upon administration in mouse models of human, CXCR4 colorectal cancer, accumulates in primary tumor at levels significantly higher than the parental T22-GFP-H6 HA2-lacking version. The in vivo application of a CXCR4 antagonist has confirmed the prevalence of the CXCR4 tumor tissue selectivity over unspecific cell penetration, upon systemic administration of the material. Such specificity is combined with improved endosomal escape, what overall results in a precise and highly efficient tumor biodistribution. These data strongly support the functional recruitment as a convenient approach to generate protein materials for clinical applications. More precisely, they also support the unexpected concept that enhancing the unspecific membrane activity of a protein material does not necessarily compromise, but it can even improve, the selective cell targeting offered by an accompanying functional module. Statement of Significance: We have shown here that the combination of cell-penetrating and tumor cell-targeting peptides dramatically enhances precise tumor accumulation of protein-only nanoparticles intended for selective drug delivery, in mouse models of human colorectal cancer. This fact is a step forward for the rational design of multifunctional protein nanomaterials for improved cancer therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assembly of histidine-rich protein materials controlled through divalent cations

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Saccardo, Paolo|||0000-0002-3092-1404
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Nanostructured protein materials show exciting biomedical applications, since both structure and function can be genetically programmed. In particular, self-assembling histidine-rich proteins benefit from functional plasticity that allows the generation of protein-only nanoparticles for cell targeted drug delivery. However, the rational development of constructs with improved functions is limited by a poor control of the oligomerization process. By exploring cross-interactions between histidine-tagged building blocks, we have identified a critical architectonic role of divalent cations. The obtained data instruct about how histidine-rich protein materials can be assembled, disassembled and reassembled within the nanoscale through the stoichiometric manipulation of divalent ions, in a biochemical approach to biomaterials design. Statement of Significance: Divalent metal and non-metal cations such as Ni, Cu Ca and Zn have been identified as unexpected molecular tools to control the assembling, disassembling and reassembling of histidine-rich protein materials at the nanoscale. Their stoichiometric manipulation allows generating defined protein-protein cross-molecular contacts between building blocks, for a powerful nano-biochemical manipulation of the material's architecture.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells

  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Baltà Foix, Ricardo
  • Cámara-Sánchez, Patricia|||0000-0003-1958-9735
  • Gener, Petra|||0000-0002-2250-570X
  • Jara, José Juan
  • Pulido, Daniel|||0000-0002-2841-194X
  • Serna, Naroa|||0000-0001-5682-8198
  • Schwartz, Simon|||0000-0001-8297-7971
  • Royo, Miriam|||0000-0001-5292-0819
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Vázquez, Esther|||0000-0003-1052-0424
Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-negative human breast cancers. Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion. The further engineering of this protein into the modular construct F3-RK-GFP-H6 and the subsequent construct F3-RK-PE24-H6 resulted in self-assembling polypeptides that organize as discrete and regular nanoparticles. These materials, 15-20 nm in size, show enhanced nucleolin-dependent cell penetrability. We show that the F3-RK-PE24-H6, based on the Pseudomonas aeruginosa exotoxin A (PE24) as a core functional domain, is highly cytotoxic over target cells. The combination of F3, the cationic peptide (RK), and the toxin domain PE24 in such unusual presentation appears as a promising approach to cell-targeted drug carriers in breast cancers and addresses selective drug delivery in otherwise difficult-to-treat triple-negative breast cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Serna, Naroa|||0000-0001-5682-8198
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Modular protein engineering is suited to recruit complex and multiple functionalities in single-chain polypeptides. Although still unexplored in a systematic way, it is anticipated that the positioning of functional domains would impact and refine these activities, including the ability to organize as supramolecular entities and to generate multifunctional protein materials. To explore this concept, we have repositioned functional segments in the modular protein T22-GFP-H6 and characterized the resulting alternative fusions. In T22-GFP-H6, the combination of T22 and H6 promotes self-assembling as regular nanoparticles and selective binding and internalization of this material in CXCR4-overexpressing tumor cells, making them appealing as vehicles for selective drug delivery. The results show that the pleiotropic activities are dramatically affected in module-swapped constructs, proving the need of a carboxy terminal positioning of H6 for protein self-assembling, and the accommodation of T22 at the amino terminus as a requisite for CXCR4 cell binding and internalization. Furthermore, the failure of self-assembling as regular oligomers reduces cellular penetrability of the fusions while keeping the specificity of the T22-CXCR4 interaction. All these data instruct how multifunctional nanoscale protein carriers can be designed for smart, protein-driven drug delivery, not only for the treatment of CXCR4 human neoplasias, but also for the development of anti-HIV drugs and other pathologies in which CXCR4 is a relevant homing marker.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity

  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sala, Rita
  • Serna, Naroa|||0000-0001-5682-8198
  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
A functional 29 amino acid-segment of the helix α5 from the human BAX protein has been engineered for production in recombinant bacteria as self-assembling, GFP-containing fluorescent nanoparticles, which are targeted to the tumoral marker CXCR4. These nanoparticles, of around 34 nm in diameter, show a moderate tumor biodistribution and limited antitumoral effect when systemically administered to mouse models of human CXCR4 colorectal cancer (at 300 μg dose). However, if such BAX nanoparticles are co-administered in cocktail with equivalent nanoparticulate versions of BAK and PUMA proteins at the same total protein dose (300 μg), protein biodistribution and stability in tumor is largely improved, as determined by fluorescence profiles. This fact leads to a potent and faster destruction of tumor tissues when compared to individual pro-apoptotic factors. The analysis and interpretation of the boosted effect, from both the structural and functional sides, offers clues for the design of more efficient nanomedicines and theragnostic agents in oncology based on precise cocktails of human proteins. Statement of significance: Several human pro-apoptotic peptides (namely BAK, BAX and PUMA) have been engineered as self-assembling protein nanoparticles targeted to the tumoral marker CXCR4. The systemic administration of the same final amounts of those materials as single drugs, or as combinations of two or three of them, shows disparate intensities of antitumoral effects in a mouse model of human colorectal cancer, which are boosted in the triple combination on a non-additive basis. The superiority of the combined administration of pro-apoptotic agents, acting at different levels of the apoptotic cascade, opens a plethora of possibilities for the development of effective and selective cancer therapies based on the precise cocktailing of pro-apoptotic nanoparticulate agents. ing Research Center on Bioengineering, Biomaterials and Nanomedicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles

  • Díaz, Raquel
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
The controlled oligomerization of functional proteins at the nanoscale offers the possibility to design and produce, by recombinant DNA technologies and in cell factories, improved materials and drugs in form of nanoparticles. A recombinant version of the scorpion toxin chlorotoxin (CTX), which has attracted interest due to its ability to preferentially bind cancer cells, has been engineered to self-assemble as regular 12 nm-nanoparticles that penetrate cultured cells with the same receptor-specificity than the natural toxin. These materials, that appear as promising, biocompatible and biodegradable drug carriers for cell-targeted therapy of glioma also exhibit a mild but still significant cytotoxic activity associated to the recombinant toxin, that simultaneously acts as both driver and therapeutic agent. In addition, the manipulation of the CTX-flanking regions shows a potent impact on the performance of the nanoparticles, supporting a high functional versatility of CTX-based constructs, regulatable by conventional genetic engineering and adaptable to specific therapeutic situations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering protein venoms as self-assembling CXCR4-targeted cytotoxic nanoparticles

  • Serna, Naroa|||0000-0001-5682-8198
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Protein venoms are effective cytotoxic molecules that when conveniently targeted to tumoral markers can be exploited as promising anticancer drugs. Here, it is explored whether the structurally unrelated melittin, gomesin, and CLIP71 could be functionally active when engineered, in form of GFP fusions, as self-assembling multimeric nanoparticles. Incorporated in modular constructs including a C-terminal polyhistidine tag and an N-terminal peptidic ligand of the cytokine receptor CXCR4 (overexpressed in more than 20 human neoplasias), these venoms are well produced in recombinant bacteria as proteolytically stable regular nanoparticles ranging between 12 and 35 nm. Being highly fluorescent, these materials selectively penetrate, label, and kill CXCR4 tumor cells in a CXCR4-dependent fashion. The obtained data support the concept of recombinant venoms as promising drugs, through the precise formulation as tumor-targeted nanomaterials for selective theragnostic applications in CXCR4 cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles

  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
The membrane pore-forming activities of the antimicrobial peptide GWH1 have been evaluated in combination with the CXCR4-binding properties of the peptide T22, in self-assembling protein nanoparticles with high clinical potential. The resulting materials, of 25 nm in size and with regular morphologies, show a dramatically improved cell penetrability into CXCR4 cells (more than 10-fold) and enhanced endosomal escape (the lysosomal degradation dropping from 90% to 50%), when compared with equivalent protein nanoparticles lacking GWH1. These data reveal that GWH1 retains its potent membrane activity in form of nanostructured protein complexes. On the other hand, the specificity of T22 in the CXCR4 receptor binding is subsequently minimized but, unexpectedly, not abolished by the presence of the antimicrobial peptide. The functional combination T22-GWH1 results in 30% of the nanoparticles entering cells via CXCR4 while also exploiting pore-based uptake. Such functional materials are capable to selectively deliver highly potent cytotoxic drugs upon chemical conjugation, promoting CXCR4-dependent cell death. These data support the further development of GWH1-empowered cell-targeted proteins as nanoscale drug carriers for precision medicines. This is a very promising approach to overcome lysosomal degradation of protein nanostructured materials with therapeutic value.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanostructured antimicrobial peptides, The last push towards clinics

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Serna, Naroa|||0000-0001-5682-8198
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Peptide drugs hold great potential for the treatment of infectious diseases due to their unconventional mechanisms of action, biocompatibility, biodegradability and ease of synthesis and modification. The increasing rising of bacterial strains resistant to classical antibiotics have pushed the development of new peptide-based antimicrobial therapies. In this context, over the past few years, different approaches have reached a clinical approval. Furthermore, the application of nanotechnological principles to the design of antimicrobial peptide-based composites increases even more the already known benefits of antimicrobial peptides as competent protein drugs. Then, we provide here an overview of the current strategies for antimicrobial peptide discovery and modification and the status of such peptides already under clinical development. In addition, we summarize the innovative formulation strategies for their application, focusing on the controlled self-assembly for the fabrication of antimicrobial nanostructures without the assistance of external nanocarriers, and with emphasis on bioengineering, design of ultra-short peptides and rising insights in bacterial selectivity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering secretory amyloids for remote and highly selective destruction of metastatic foci

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sala, Rita
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Serna, Naroa|||0000-0001-5682-8198
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Functional amyloids produced in bacteria as nanoscale inclusion bodies are intriguing but poorly explored protein materials with wide therapeutic potential. Since they release functional polypeptides under physiological conditions, these materials can be potentially tailored as mimetic of secretory granules for slow systemic delivery of smart protein drugs. To explore this possibility, bacterial inclusion bodies formed by a self-assembled, tumor-targeted Pseudomonas exotoxin (PE24) are administered subcutaneously in mouse models of human metastatic colorectal cancer, for sustained secretion of tumor-targeted therapeutic nanoparticles. These proteins are functionalized with a peptidic ligand of CXCR4, a chemokine receptor overexpressed in metastatic cancer stem cells that confers high selective cytotoxicity in vitro and in vivo. In the mouse models of human colorectal cancer, time-deferred anticancer activity is detected after the subcutaneous deposition of 500 µg of PE24-based amyloids, which promotes a dramatic arrest of tumor growth in the absence of side toxicity. In addition, long-term prevention of lymphatic, hematogenous, and peritoneal metastases is achieved. These results reveal the biomedical potential and versatility of bacterial inclusion bodies as novel tunable secretory materials usable in delivery, and they also instruct how therapeutic proteins, even with high functional and structural complexity, can be packaged in this convenient format.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP

  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roldán, Mònica
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Benítez, Raúl|||0000-0002-8782-9406
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Fluorescent proteins are useful imaging and theranostic agents, but their potential superiority over alternative dyes is weakened by substantial photobleaching under irradiation. Enhancing protein photostability has been attempted through diverse strategies, with irregular results and limited applicability. In this context, we wondered if the controlled oligomerization of Green Fluorescent Protein (GFP) as nanoscale supramolecular complexes could stabilize the fluorophore through the newly formed protein-protein contacts, and thus, enhance its global photostability. For that, we have here analyzed the photobleaching profile of several GFP versions, engineered to self-assemble as tumour-homing nanoparticles with different targeting, size and structural stability. This has been done under prolonged irradiation in confocal laser scanning microscopy and by small-angle X-ray scattering. The results show that the oligomerization of GFP at the nanoscale enhances, by more than seven-fold, the stability of fluorescence emission. Interestingly, GFP nanoparticles are much more resistant to X-ray damage than the building block counterparts, indicating that the gained photostability is linked to enhanced structural resistance to radiation. Therefore, the controlled oligomerization of self-assembling fluorescent proteins as protein nanoparticles is a simple, versatile and powerful method to enhance their photostability for uses in precision imaging and therapy. Statement of significance: Fluorescent protein assembly into regular and highly symmetric nanoscale structures has been identified to confer enhanced structural stability against radiation stresses dramatically reducing their photobleaching. Being this the main bottleneck in the use of fluorescent proteins for imaging and theranostics, this protein architecture engineering principle appears as a powerful method to enhance their photostability for a broad applicability in precision imaging, drug delivery and theranostics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Conformational conversion during controlled oligomerization into nonamylogenic protein nanoparticles

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Protein materials are rapidly gaining interest in materials sciences and nanomedicine because of their intrinsic biocompatibility and full biodegradability. The controlled construction of supramolecular entities relies on the controlled oligomerization of individual polypeptides, achievable through different strategies. Because of the potential toxicity of amyloids, those based on alternative molecular organizations are particularly appealing, but the structural bases on nonamylogenic oligomerization remain poorly studied. We have applied spectrofluorimetry and spectropolarimetry to identify the conformational conversion during the oligomerization of His-tagged cationic stretches into regular nanoparticles ranging around 11 nm, useful for tumor-targeted drug delivery. We demonstrate that the novel conformation acquired by the proteins, as building blocks of these supramolecular assemblies, shows different extents of compactness and results in a beta structure enrichment that enhances their structural stability. The conformational profiling presented here offers clear clues for understanding and tailoring the process of nanoparticle formation through the use of cationic and histidine rich stretches in the context of protein materials usable in advanced nanomedical strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein-based therapeutic killing for cancer therapies

  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Díaz, Raquel
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
The treatment of some high-incidence human diseases is based on therapeutic cell killing. In cancer this is mainly achieved by chemical drugs that are systemically administered to reach effective toxic doses. As an innovative alternative, cytotoxic proteins identified in nature can be adapted as precise therapeutic agents. For example, individual toxins and venom components, proapoptotic factors, and antimicrobial peptides from bacteria, animals, plants, and humans have been engineered as highly potent drugs. In addition to the intrinsic cytotoxic activities of these constructs, their biological fabrication by DNA recombination allows the recruitment, in single pharmacological entities, of diverse functions of clinical interest such as specific cell-surface receptor binding, self-activation, and self-assembling as nanoparticulate materials, with wide applicability in cell-targeted oncotherapy and theragnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs

  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sala, Rita
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Roldán, Mònica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Loading capacity and drug leakage from vehicles during circulation in blood is a major concern when developing nanoparticle-based cell-targeted cytotoxics. To circumvent this potential issue it would be convenient the engineering of drugs as self-delivered nanoscale entities, devoid of any heterologous carriers. In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic materials targeted to CXCR4 cancer stem cells. The systemic administration of both nanostructured drugs in a colorectal cancer xenograft mouse model promotes efficient and specific local destruction of target tumor tissues and a significant reduction of the tumor volume. This observation strongly supports the concept of intrinsically functional protein nanoparticles, which having a dual role as drug and carrier, are designed to be administered without the assistance of heterologous vehicles.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Release of targeted protein nanoparticles from functional bacterial amyloids, A death star-like approach

  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Sala, Rita
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Here we describe a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines the high performance of pNP, regarding specific cell targeting and biodistribution with the IB supramolecular organization, stability and cost effectiveness. This renders a platform able to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in tumor cells in a CXCR4 colorectal cancer xenograft model. In addition, the proposed system could be potentially adapted to any other protein construct offering a plethora of possible new therapeutic applications in nanomedicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Cubarsi, Rafael
  • Roldán, Mònica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Azzoni, Adriano Rodrigues|||0000-0003-0696-4663
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Arginine-rich protein motifs have been described as potent cell-penetrating peptides (CPPs) but also as rather specific ligands of the cell surface chemokine receptor CXCR4, involved in the infection by the human immunodeficiency virus (HIV). Polyarginines are commonly used to functionalize nanoscale vehicles for gene therapy and drug delivery, aimed to enhance cell penetrability of the therapeutic cargo. However, under which conditions these peptides do act as either unspecific or specific ligands is unknown. We have here explored the cell penetrability of differently charged polyarginines in two alternative presentations, namely as unassembled fusion proteins or assembled in multimeric protein nanoparticles. By this, we have observed that arginine-rich peptides switch between receptor-mediated and receptor-independent mechanisms of cell penetration. The relative weight of these activities is determined by the electrostatic charge of the construct and the oligomerization status of the nanoscale material, both regulatable by conventional protein engineering approaches.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein nanoparticles are nontoxic, tuneable cell stressors

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Roldán, Mònica
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Serna, Naroa|||0000-0001-5682-8198
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Azzoni, Adriano Rodrigues|||0000-0003-0696-4663
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Aim: nanoparticle-cell interactions can promote cell toxicity and stimulate particular behavioral patterns, but cell responses to protein nanomaterials have been poorly studied. - Results: by repositioning oligomerization domains in a simple, modular self-assembling protein platform, we have generated closely related but distinguishable homomeric nanoparticles. Composed by building blocks with modular domains arranged in different order, they share amino acid composition. These materials, once exposed to cultured cells, are differentially internalized in absence of toxicity and trigger distinctive cell adaptive responses, monitored by the emission of tubular filopodia and enhanced drug sensitivity. - Conclusion: the capability to rapidly modulate such cell responses by conventional protein engineering reveals protein nanoparticles as tuneable, versatile and potent cell stressors for cell-targeted conditioning.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 + Diffuse Large B-Cell Lymphoma Cells

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Álamo, Patricia|||0000-0003-0510-5701
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limited by severe side effects. Therefore, we chose to improve the therapeutic window of the MTA monomethyl auristatin E developing a nanoconjugate, T22-AUR, that selectively targets the CXCR4 receptor, which is overexpressed in many DLBCL cells (CXCR4 +) and associated with poor prognosis. The T22-AUR specificity towards CXCR4 receptor was performed by flow cytometry in different DLBCL cell lines and running biodistribution assays in a subcutaneous mouse model bearing CXCR4 + DLBCL cells. Moreover, we determined T22-AUR cytotoxicity using cell viability assays, cell cycle analysis, DAPI staining and immunohistochemistry. Finally, the T22-AUR antineoplastic effect was evaluated in vivo in an extranodal CXCR4 + DLBCL mouse model whereas the toxicity analysis was assessed by histopathology in non-infiltrated mouse organs and by in vitro cytotoxic assays in human PBMCs. We demonstrate that the T22-AUR nanoconjugate displays CXCR4-dependent targeting and internalization in CXCR4 + DLBCL cells in vitro as well as in a subcutaneous DLBCL mouse model. Moreover, it shows high cytotoxic effect in CXCR4 + DLBCL cells, including induction of G2/M mitotic arrest, DNA damage, mitotic catastrophe and apoptosis. Furthermore, the nanoconjugate shows a potent reduction in lymphoma mouse dissemination without histopathological alterations in non-DLBCL infiltrated organs. Importantly, T22-AUR also exhibits lack of toxicity in human PBMCs. T22-AUR exerts in vitro and in vivo anticancer effect on CXCR4 + DLBCL cells without off-target toxicity. Thus, T22-AUR promises to become an effective therapy for CXCR4 + DLBCL patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

  • Pesarrodona, Mireia
  • Jauset González, Antoni
  • Sánchez-Chardi, Alejandro
  • Seras Franzoso, Joaquin
  • Baltà Foix, Ricardo
  • Mancilla Zamora, Sandra
  • Fernández Amurgo, Yolanda
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Biofabrication; Cancer therapy; Functional amyloids, Biofabricación; Terapia contra el cáncer; Amiloides funcionales, Biofabricació; Teràpia contra el càncer; Amiloides funcionals, Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins., This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award